AND_1762.jpg

Mazanti advises Sunstone on its €5 million investment in Forendo Pharma Ltd.

Mazanti Transactions has advised the venture capital firm Sunstone in connection with its €5 million investment into the Finnish women’s health company Forendo Pharma Ltd. Founded in 2013 by leading academic endocrinology professionals and Finnish drug development pioneers, Forendo Pharma is a clinical stage drug development company focusing on novel treatments in women’s health. The investment from Sunstone is designated to finance clinical studies in treatment of endometriosis.

Sunstone focuses on developing and expanding early-stage pharmaceutical companies with strong potential to achieve global success in their markets. With this investment they will be joining a collective of reputable active international investors such as Novo Seeds, Novartis Venture Fund, Vesalius Biocapital III and M Ventures (Merck). General Partner at Sunstone Claus Andersson, who will join Forendo Pharma’s board of directors, comments that:

“Sunstone sees women’s health as an area with immense need of investments and with trending popularity. Endometriosis is a perfect example as approximately 8% of all pre-menopausal women are affected with moderate to severe pain, infertility, and impaired quality of life as a consequence.  We are very pleased to make this first investment under our new Fund IV, which earlier this year had its first closing at €80 million, and with a target of €150 million at final closing.”

For more information related to the transaction, read here.